STERIS (NYSE:STE) Director Sells $956,795.24 in Stock

Key Points

• STERIS director Mohsen Sohi sold 4,058 shares at an average price of $235.78, generating $956,795.24 and reducing his direct holdings by 14.31% to 24,305 shares.
• STERIS reported quarterly EPS of $2.59, beating analysts’ $2.49 estimate, while revenue rose 7.3% year over year to $1.49 billion. The company provided fiscal 2027 EPS guidance of $11.00–$11.30.
• The company increased its quarterly dividend from $0.63 to $0.69 per share, equivalent to an annualized $2.76 dividend and a 1.2% yield; analysts maintain a “Moderate Buy” consensus with an average $271.33 price target.

STERIS plc (NYSE:STE - Get Free Report) Director Mohsen Sohi sold 4,058 shares of the company's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $235.78, for a total value of $956,795.24. Following the completion of the transaction, the director directly owned 24,305 shares of the company's stock, valued at $5,730,632.90. This represents a 14.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

STERIS Trading Down 0.8%

NYSE STE traded down $1.98 during trading hours on Wednesday, reaching $236.25. The company's stock had a trading volume of 648,288 shares, compared to its average volume of 801,121. The firm has a fifty day simple moving average of $215.99 and a 200-day simple moving average of $224.88. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.91 and a quick ratio of 1.35. STERIS plc has a 52 week low of $195.14 and a 52 week high of $269.44. The stock has a market cap of $23.03 billion, a P/E ratio of 28.88 and a beta of 0.91.

STERIS (NYSE:STE - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.49 by $0.10. STERIS had a net margin of 13.34% and a return on equity of 14.34%. The firm had revenue of $1.49 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the firm posted $2.34 EPS. The company's revenue for the quarter was up 7.3% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Equities analysts forecast that STERIS plc will post 11.09 earnings per share for the current fiscal year.

STERIS Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Friday, September 4th will be given a dividend of $0.69 per share. The ex-dividend date of this dividend is Friday, September 4th. This represents a $2.76 annualized dividend and a yield of 1.2%. This is an increase from STERIS's previous quarterly dividend of $0.63. STERIS's dividend payout ratio is 33.74%.

Analyst Ratings Changes

STE has been the topic of a number of analyst reports. Weiss Ratings lowered STERIS from a "hold (c+)" rating to a "hold (c)" rating in a research report on Wednesday, May 27th. Piper Sandler restated an "overweight" rating and set a $275.00 price objective (up from $270.00) on shares of STERIS in a research report on Friday, August 7th. UBS Group cut their price objective on STERIS from $275.00 to $270.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. Wall Street Zen upgraded STERIS from a "hold" rating to a "buy" rating in a report on Sunday. Finally, KeyCorp decreased their target price on shares of STERIS from $291.00 to $269.00 and set an "overweight" rating for the company in a research report on Wednesday, May 13th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, STERIS has a consensus rating of "Moderate Buy" and an average target price of $271.33.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Western Wealth Management LLC acquired a new stake in STERIS in the first quarter worth $25,000. Elevation Wealth Partners LLC raised its holdings in shares of STERIS by 1,130.0% during the second quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 113 shares during the period. Activest Wealth Management boosted its position in shares of STERIS by 423.8% during the 4th quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 89 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new position in shares of STERIS during the 4th quarter worth about $28,000. Finally, Geneos Wealth Management Inc. grew its stake in shares of STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider's stock valued at $29,000 after buying an additional 104 shares during the period. Institutional investors and hedge funds own 94.69% of the company's stock.

About STERIS

STERIS Corporation NYSE: STE is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source